Metformin's primary safety concern in patients with impaired renal function is its ability to cause lactic acidosis. 

Systemic review shows sex, age, comorbid conditions, insulin use, and several out-of-range lab predictors on hospital admission, all play a role in COVID-19 severity.

Glucose-lowering medication can influence COVID-19 pathogenesis and could have implications for treating patients with diabetes and COVID-19.

Are the mortality and cardiovascular benefits of SGLT-2 inhibitors limited to patients with type 2 diabetes who have established cardiovascular disease and renal disease?

Blood sugar levels of 70 to 160 mg/dL are considered normal, and anything outside these levels could negatively affect patients.

Are socioeconomic factors and obesity independently related to diabetes prevalence?

Long-term diabetes may lead to signs of cognitive decline in Latino patients as early as middle age.

Dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1RAs create an additive effect for increased anti-inflammation and vascular protection.

The FDA has approved empagliflozin Breakthrough therapy for patients with heart failure with preserved ejection fraction (HFpEF).

Measuring waist circumference could provide an inexpensive way to assess risk of developing insulin resistance.